Tag - ARCT

Markets

Cantor starts Arcturus Therapeutics at OW; PT $71

Cantor Fitzgerald launched coverage of Arcturus Therapeutics (NASDAQ:ARCT) with an “overweight” rating and $71 price target. The stock closed at $35.94 on July 1. Arcturus is leveraging its proprietary lipid-based...

July 2, 2021

Markets

Brookline doubles Arcturus Therapeutics PT to $64 from $32

Brookline Capital Markets raised its price target for Arcturus Therapeutics (NASDAQ:ARCT) to $64 from $32, citing positive immunogenicity data for its COVID-19 vaccine. The stock was quoted at $44.88, up $5.65, in...

May 11, 2020

Markets

HCW ups Arcturus Therapeutics PT to $62 from $26 on COVID-19 data

H.C. Wainwright more than doubled the price target for Arcturus Therapeutics (NASDAQ:ARCT) to $62 from $26, citing impressive preclinical results from its COVID-19 vaccine candidate. Shares of Arcturus jumped $7.96, to...

April 28, 2020

Markets

Brookline starts Arcturus Therapeutics at buy; PT $25

Brookline Capital Markets launched coverage of Arcturus Therapeutics (NASDAQ:ARCT) with a “buy” rating and price target of $25. The stock closed at $11.80 on July 24. Arcturus is developing RNA-based therapies...

July 25, 2019

Tag - ARCT

Cantor starts Arcturus Therapeutics at OW; PT $71

Brookline doubles Arcturus Therapeutics PT to $64 from $32

HCW ups Arcturus Therapeutics PT to $62 from $26 on COVID-19 data

Brookline starts Arcturus Therapeutics at buy; PT $25

General

More